Clinical observation of transarterial hyperthermic perfusion chemotherapy combined with superselective arterial embolization for the treatment of unresectable colorectal cancer liver metastasis

doi:10.3877/cma.j.issn.2095-5782.2018.01.008

Abstract

Abstract:

Objective:

To evaluate the effect of transarterial hyperthemic perfusion chemotherapy combined with arterial superselective embolization for the treatment of unresectable colorectal cancer liver metastasis.

Methods:

A retrospective analysis of the clinical data of 39 cases with colorectal cancer liver metastasis was conducted. The treatment group included 22 cases. Transarterial hyperthemic perfusion (51 ℃, 1 h) was performed in superior mesenteric artery and hepatic artery respectively. And then super selective artery embolization was performed in the feeding artery of hepatic lesions. Control group included 17 cases who received traditional transcatheter arterial chemoembolization (TACE) . The short-term effect was evaluated by objective response rate and clinical benefit rate. One year survival rate was used to evaluate the long-term effect. At the same time, adverse reactions of two groups were recorded.

Results:

There was no significant difference between the basic clinical characteristics of patients in two groups. The objective effective rate showed no significant difference (27.3% vs. 23.5%, P>0.05) between the two groups and the clinical benefit rate also showed no significant difference (81.8% vs. 76.5%, P>0.05) . However, the one year survival rate of study group was significantly higher than the control group (63.2% vs. 46.7%, P< 0.05) . There were no artery vasospasm, occlusion, or any other serious adverse reactions in two groups.

Conclusions:

The long-term effect of transarterial hyperthemic perfusion chemotherapy combined with arterial superselective embolization on unresectable colorectal cancer liver metastasis is superior to that of conventional TACE.

Key words: Transarterial hyperthemic perfusion chemotherapy, Transcatheter arterial chemoembolization, Liver metastasis of colorectal cancer

Yapan Guo, Pengcheng Sun, Jueqing Lu, Biyun Zhu, Jing Sun, Xin Zhang. Clinical observation of transarterial hyperthermic perfusion chemotherapy combined with superselective arterial embolization for the treatment of unresectable colorectal cancer liver metastasis[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2018, 06(01): 32-36.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjrfsxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5782.2018.01.008

https://zhjrfsxdzzz.cma-cmc.com.cn/EN/Y2018/V06/I01/32

Figures/Tables 4

References 14

[1]	Siegel RL, Miller KD, Jemal A. Colorectal cancer mortality rates in adults aged 20 to 54 years in the United States, 1970-2014[J]. JAMA, 2017, 318(6):572-574.
[2]	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
[3]	蔡建强，蔡三军，秦新裕，等.结直肠癌肝转移诊断和综合治疗指南（2016）[J].中国实用外科杂志，2016，15(8):858-869.
[4]	de Baere T, Tselikas L, Boige V, et al. Intra-arterial therapies for colorectal cancer liver metastases（radioembolization excluded）[J]. Bull Cancer, 2017, 104(5):402-406.
[5]	中华人民共和国国家卫生和计划生育委员会.原发性肝癌诊疗规范（2017年版）[J].临床肝胆病杂志，2017，33(8):1419-1431.
[6]	Lencioni R, Montal R, Torres F, et al. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC[J]. J Hepatol, 2017, 66(6):1166-1172.
[7]	姜松，李桂杰，周祝谦, 等. CalliSpheres载药栓塞微球治疗中晚期肝癌临床效果评价[J/CD].中华介入放射学电子杂志, 2017, 5(3):174-178.
[8]	Lahrsow M, Albrecht MH, Bickford MW, et al. Predicting treatment response of colorectal cancer liver metastases to conventional lipiodol-based transarterial chemoembolization using diffusion-weighted mr imaging：value of pretreatment apparent diffusion coefficients（ADC）and ADC changes under therapy[J]. Cardiovasc Intervent Radiol, 2017, 40(6):852-859.
[9]	Gaba RC, Lewandowski RJ, Hickey R, et al. Transcatheter therapy for hepatic malignancy：standardization of terminology and reporting criteria[J]. J Vasc Interv Radiol, 2016, 27(4):457-473.
[10]	Ba M, Cui S, Wang B, et al. Bladder intracavitary hyperthermic perfusion chemotherapy for the prevention of recurrence of non-muscle invasive bladder cancer after transurethral resection[J]. Oncol Rep, 2017, 37(5):2761-2770.
[11]	Zhang T, Pan Q, Xiao S, et al. Docetaxel combined with intraperitoneal hyperthermic perfusion chemotherapy and hyperthermia in the treatment of advanced ovarian cancer[J]. Oncol Lett, 2016, 11(5):3287-3292.
[12]	李毅斌，曹漫明，胡喜钢，等．射频消融术联合肝动脉化疗栓塞及西妥昔单抗治疗结直肠癌肝转移的疗效评价[J].介入放射学杂志，2016，25(2):129-133.
[13]	秦叔逵，杨柳青，李进，等．雷替曲塞单药治疗不能耐受或不适合5-FU/CF治疗的局部晚期或复发转移性结直肠癌的全国多中心Ⅳ期临床研究[J].临床肿瘤学杂志，2017，22(3):203-208.
[14]	刘毅勇.兔肝VX2瘤两种介入性热化疗方法的对比实验研究[J].现代肿瘤医学，2015，23(3):299-302.

临床特征		研究组(n=22)	对照组(n＝17)	统计量	P值
性别		?	?	χ²=0.289	0.590
?	男	16	11	?	?
?	女	6	6	?	?
年龄（岁）		60.6±12.1	63±12.4	t=0.239	0.822
原发灶部位		?	?	χ²=0.179	0.915
?	右半结肠	5	3	?	?
?	左半结肠	9	7	?	?
?	直肠	8	7	?	?
ECOG评分		?	?	χ²=0.175	0.916
?	0分	8	6	?	?
?	1分	7	7	?	?
?	2分	4	4	?	?
Child-Pugh分级		?	?	χ²=0.002	0.966
?	A级	18	14	?	?
?	B级	4	3	?	?
肝内靶病灶直径(cm)		12.0±2.2	11.5±1.2	t=0.346	0.747
肝外转移灶		?	?	χ²=0.052	0.819
?	有	15	11	?	?
?	无	7	6	?	?
外科手术史		?	?	χ²=0.084	0.959
?	切除术后复发	11	8	?	?
?	姑息性造瘘术	9	7	?	?
?	无	2	2	?	?

临床特征		研究组(n=22)	对照组(n＝17)	统计量	P值
性别		?	?	χ²=0.289	0.590
?	男	16	11	?	?
?	女	6	6	?	?
年龄（岁）		60.6±12.1	63±12.4	t=0.239	0.822
原发灶部位		?	?	χ²=0.179	0.915
?	右半结肠	5	3	?	?
?	左半结肠	9	7	?	?
?	直肠	8	7	?	?
ECOG评分		?	?	χ²=0.175	0.916
?	0分	8	6	?	?
?	1分	7	7	?	?
?	2分	4	4	?	?
Child-Pugh分级		?	?	χ²=0.002	0.966
?	A级	18	14	?	?
?	B级	4	3	?	?
肝内靶病灶直径(cm)		12.0±2.2	11.5±1.2	t=0.346	0.747
肝外转移灶		?	?	χ²=0.052	0.819
?	有	15	11	?	?
?	无	7	6	?	?
外科手术史		?	?	χ²=0.084	0.959
?	切除术后复发	11	8	?	?
?	姑息性造瘘术	9	7	?	?
?	无	2	2	?	?

组别	例数	CR	PR	SD	PD	ORR(%)	CBR(%)
研究组	22	0	6	12	4	27.2	81.8
对照组	17	0	4	9	4	23.5	76.5
χ²值	?	?	?	?	?	0.070	0.168
P值	?	?	?	?	?	0.791	0.682

组别	例数	CR	PR	SD	PD	ORR(%)	CBR(%)
研究组	22	0	6	12	4	27.2	81.8
对照组	17	0	4	9	4	23.5	76.5
χ²值	?	?	?	?	?	0.070	0.168
P值	?	?	?	?	?	0.791	0.682

[1]	Hongtao Tang, Kun He. Progress and prospects of interventional therapy for advanced hepatocellular carcinoma [J]. Chinese Archives of General Surgery(Electronic Edition), 2024, 18(04): 305-308.
[2]	Qian Yang, Cuifang Li, Wanqiu Zhang. Analysis of short-term and long-term prognosis and influencing factors of primary liver cancer with spontaneous ruptured hemorrhage after emergency TACE surgery [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 33-36.
[3]	Jianmei Li, Jingjuan Deng, Qian Yang. Safety and follow-up evaluation of the combined treatment of hepatocellular carcinoma with hepatic cirrhosis and portal hypertension [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 41-44.
[4]	Weihua Yu, Yaogang Fan, Yigang Wang, Kai Yang, Su Li. Long-term follow-up evaluation of surgical treatment of 30 cases of hepatocellular carcinoma with hepatic vein tumor thrombus [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2021, 15(04): 388-391.
[5]	Chengkai Yang, Jiamian Xu, Huaxiang Wang, Peng Lin, Xiaoya Wu, Cheng′en Hong, Qiucheng Cai, Lizhi Lyu, Fan Pan, Yi Jiang. Postoperative efficacy of preoperative transcatheter arterial chemoembolization therapy for liver transplant recipients with hepatocellular carcinoma meeting Hangzhou criteria [J]. Chinese Journal of Transplantation(Electronic Edition), 2022, 16(03): 147-152.
[6]	Yanjing Song, jiangchun Qiao, Jinghai Song. Right hepatectomy of CNLC stage Ⅲa hepatocellular carcinoma after successful conversion by TACE combined with targeted therapy and immunotherapy: a case report [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(02): 227-230.
[7]	Yu Zhang, Lingxiang Yu, Yongping Yang, Dexi Zhao, Guanghao Diao, Muyi Yang, Liang Zhao, Jia Liu, Peng Li, Ning Zhang, Hui Ren. Clinical efficacy of hepatectomy after down-staging treatments in patients with stage Ⅲa primary liver cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(01): 78-82.
[8]	Le Bao, Ying Liu, Youbin Wang, Long Chen, Yuzhi Zhu, Shuang Liang, Hetai Quan, Pengfei Li. Clinical application of Huanyang Tongluo moxibustion in interventional therapy of primary hepatic carcinoma [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(03): 197-202.
[9]	Pengwei Zhang, Chaofeng Yang, Yang Li. Research progress of interventional therapy of colorectal liver metastasis [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(02): 177-182.
[10]	Xiaowen Cai, Huijing Li, Jie Qiu, Yifan Yang, Suxian Wu, Yutong Lin, Qiuna He. Construction and verification of a pain risk prediction model for patients with liver cancer after TACE [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(08): 722-728.
[11]	Haoran Cui, Junpeng Gu, Weixin Ren. Progress in the treatment of liver cancer with portal vein thrombosis based on TACE [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2024, 12(01): 64-69.
[12]	Bin Zhou, Xinxian Liu. Effect of preoperative TACE on improving long-term survival in children with hepatoblastoma [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2023, 11(04): 314-317.
[13]	Xiaoyong Ge, Yahua Li, Zongming Li, Zihe Zhou, Kunpeng Wu, Yifan Li, Xinwei Han, Kewei Ren. Application progress of novel temperature-sensitive hydrogel in transcatheter arterial chemoembolization [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2023, 11(03): 268-274.
[14]	Jia Zeng, Dongfeng He. Research progress of interventional embolization materials in the treatment of liver cancer [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2023, 11(01): 62-67.
[15]	Jingyuan Hu, Yong Xie, Huan Tian, Hua Xiang, Ran Peng, Yuzhou Liu, Lu Zhou, Jian Liu, Zhuoyan Cai. Comparison of sequential TACE and portal vein embolization with portal vein embolization alone before major hepatectomy in hepatocellular carcinoma: a systematic review and meta-analysis [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2022, 10(03): 259-267.

Please choose a citation manager

Content to export